Another in a series of hearings with pharma CEOs takes place today.
intellectual property
Posted inHealth and Social Policy
On Drug Prices, Biden Opts for Talk Over Action
The administration says it has the ability to employ march-in rights to lower drug prices. When will it actually use them?
Posted inLaw and Justice
The Department of Justice’s Legal Love Letter to Moderna
This story has been retracted.
Posted inHealth and Social Policy
The Next Insulin Scandal
A generic cold medicine available in Europe also turns out to have benefits for Parkinson’s. Biden could prevent the usual effort to patent it and jack up the price.
Posted inHealth and Social Policy
Sanders Seeks Investigation of NIH Licensing Practices
The senator wants the inspector general to probe why the NIH licensed a potentially lucrative cancer drug to an obscure company linked to a former employee.
Posted inHealth and Social Policy
The NIH’s ‘How to Become a Billionaire’ Program
An obscure company affiliated with a former NIH employee is offered the exclusive license for a government-funded cancer drug.
Posted inHealth and Social Policy
We May Not Negotiate Prices for Ten Drugs After All
Rules that exempt drugs from Medicare negotiation if there’s ‘meaningful’ generic competition could whittle down the effect of the program.
Posted inMoney, Politics, and Power
The Revolving Door Threatens the Integrity of the U.S. Patent and Trademark Office
The Trump-era Patent Office director has expanded his post-government influence-peddling.
Posted inTAP
Biden’s China Policy: Less Than Meets the Eye
Today on TAP: The White House executive order on export controls is mostly window dressing—and there is already pressure to water it down.
Posted inTAP
Eminent Domain for Overpriced Drugs
Today on TAP: Exhibit A is the case of the EpiPen. It should cost a few dollars rather than the $600 or more charged by monopolist Viatris.